Again, with a caveat that this is preclinical data, but we believe that 104 is probably a very good indicator of what can be achieved with an active CD16A-positive AlloNK cell and acimtamig.
Operator: Our next question comes from the line of Yale Jen with Laidlaw & Company.
Yale Jen: You have introduced the concept or the phenomenon of double refractory patients. So my question is, does the LuminICE-203 study only include patients with this designation or this phenomena or you will have single refractory patients as well?
Andreas Harstrick: I can take this. All patients that are recruited into LuminICE have to be double refractory. So the requirement is that they have at least failed one combination chemotherapy regimen. They have failed BV and they have failed PD-1. So if you will, it’s more or less triple refractory. So it’s chemotherapy refractory, PD-1 refractory and BV refractory. So this is the patient population where we believe there’s absolutely no medical alternative and these patients are in dire need for active treatment.
Yale Jen: In terms of MD Anderson study with cord blood cell, most of the patient also has been categorized into this category or some sort of single refractory patients. So I just wanted to get some sense of how to think about the data versus the future readout you have in the first half of next year.
Andreas Harstrick: In the MD Anderson trial, the patients with Hodgkin lymphoma all fall into this category of double refractory. So all patients are BV and PD-1 refractory. As you remember, we also had a very small group of five patients of non-Hodgkin lymphoma as PD-1 is not approved for all non-Hodgkin lymphomas. We have two patients in the non-Hodgkin lymphoma cohorts that have not been exposed to PD-1 but have been exposed to BV. But again, the core populations, the Hodgkin lymphoma population, all patients have been double refractory to BV and checkpoint inhibitors.
Yale Jen: Congrats on the progress.
Operator: [Operator Instructions]. Our next question comes from the line of Sean Lee with H.C. Wainwright.
Sean Lee: I was just wondering if you could provide a bit more color on what type of data can we expect from AFM24 at ASH. You mentioned we can expect the first three cohorts.
Andreas Harstrick: Can you repeat your question?
Sean Lee: I was just wondering if you can provide a bit more color on the type of data that we can expect from ASH for AFM24 from the first three cohorts, I think, as you mentioned.
Andreas Harstrick: AFM24 will not be at ASH, but will be a separate disclosure. Obviously, data will happen in December. Now, as we’ve said, we have the three cohorts, which is EGFR wild type non-small cell lung cancer, gastric cancer and the basket cohort that was HCC, pancreatic and biliary tract. And we have about 10 to 15 – varies a little bit from cohort to cohort – responsive, evaluable patients where we will show mainly response rates. I think it’s too early to have long term follow-up data as many of these patients were recruited over the last six months, but we should have quite robust response data for these three cohorts.
Operator: Thank you. I am currently showing no further questions at this time. This concludes today’s conference call. Thank you for your participation. You may now disconnect. Everyone, have a wonderful day.
